Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olaparib - AstraZeneca

Drug Profile

Olaparib - AstraZeneca

Alternative Names: AZD 221; AZD-2281; KU-0059436; KU-59436; LYNPARZA; Lynparza; MK 7339

Latest Information Update: 30 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KuDOS Pharmaceuticals; University of Pennsylvania
  • Developer AstraZeneca; Cancer Research UK; Dana-Farber Cancer Institute; Eli Lilly; European Network of Gynaecological Oncological Trial Groups; German Breast Group; M. D. Anderson Cancer Center; Mario Negri Institute for Pharmacological Research; Massachusetts General Hospital; Merck & Co; Myriad Genetic Laboratories; Myriad Genetics; National Cancer Institute (USA); National Institute of Oncology; Netherlands Cancer Institute; NHS Greater Glasgow and Clyde; University of Manchester; University of Oxford; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Phthalazines; Piperazines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Fallopian tube cancer; Breast cancer; Pancreatic cancer; Peritoneal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase III Pancreatic cancer; Prostate cancer
  • Phase II Bladder cancer; Cervical cancer; Endometrial cancer; Gastric cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Urogenital cancer
  • Phase I/II Glioblastoma; Head and neck cancer
  • No development reported Colorectal cancer

Most Recent Events

  • 08 Feb 2019 Merck Sharp & Dohme plans the phase III KEYLYNK-010 trial for Castration-resistant prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in May 2019 (NCT03834519) (EudraCT2018-004118-16)
  • 04 Jan 2019 Phase-III clinical trials in Ovarian cancer (Combination therapy, Late-stage disease, First-line therapy) in Japan (PO)(EudraCT2017-004632-11)(NCT03737643)(JapicCTI184212)
  • 04 Jan 2019 Phase-III clinical trials in Ovarian cancer (First-line therapy, Combination therapy, Late-stage disease) in Austria (PO)(EudraCT2017-004632-11)(NCT03737643)(JapicCTI184212)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top